Michael Pillinger News Today

Growing evidence suggests that a guideline-directed, treat-to-target strategy in patients with gout not only controls the disease but also reduces cardiovascular risks.

In countries where available, low-dose benzbromarone may warrant stronger consideration in gout with renal uric acid underexcretion, researchers say.

Learn about important updates on gout treatments, gout risk factors, gout comorbidities, and more from ACR Convergence 2021, the annual meeting of the American College of Rheumatology.